SOURCE: Active Biotech

November 22, 2007 06:54 ET

Active Biotech's Election Committee Appointed

In Accordance With the Decision by the Annual General Meeting on April 19, 2007, the Election Committee Shall Consist of Representatives From the Three Largest Shareholders as at the End of October and the Chairman of the Board

LUND, SWEDEN--(Marketwire - November 22, 2007) - In accordance with the decision by the Annual General Meeting on April 19, 2007, the election committee shall consist of representatives from the three largest shareholders as at the end of October and the Chairman of the Board.

The election committee for the next Board election consists of Johnny Sommarlund for MGA Holding, Tomas Billing for Nordstjernan and Ulf Strömsten for Catella funds.

Headed by the Chairman of the Board, Mats Arnhög, the election committee will prepare a proposal for the composition of the Board to be presented to the Annual General Meeting on 7 May, 2008.

Lund, November 22, 2007
Active Biotech AB (publ)

Sven Andréasson
President and CEO

Active Biotech AB (OMX Nordic: ACTI) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57- 57 for SLE and RhuDex® for RA. In addition, the autoimmunity project I-3D is in preclinical development.

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information

  • Contact:
    Sven Andréasson
    President and CEO
    Telephone: +46 46 19 20 00